Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000950170-25-010137)

Filing Details

Accession Number:: 0000950170-25-010137
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-01-28 20:54:15
Reporting Period:: 2025-01-28

Accepted Time:: 2025-01-28 20:54:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1422143	Kura Oncology Inc.	KURA	Pharmaceutical Preparations (2834)	611547851

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1910331	James Thomas Doyle	C/O Kura Oncology, Inc. 12730 High Bluff Drive, Suite 400 San Diego CA 92130	Svp, Finance & Accounting	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-01-28	2,241	$7.87	90,901	No	4	S	Direct
Common Stock	Disposition	2025-01-28	887	$7.87	90,014	No	4	S	Direct
Common Stock	Disposition	2025-01-28	699	$7.87	89,315	No	4	S	Direct
Common Stock	Disposition	2025-01-28	1,122	$7.87	88,193	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	500	Indirect	spouse's 401(k)

Footnotes

Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24.
Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/7/22.
Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.
Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23.